search
Back to results

Carbohydrates Distribution in Pregnancy Study (CHiPS)

Primary Purpose

Gestational Diabetes Mellitus in Pregnancy

Status
Completed
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Intervention Treatment
Sponsored by
Germans Trias i Pujol Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Gestational Diabetes Mellitus in Pregnancy focused on measuring medical therapy nutrition, meal, carbohydrates, intervention, food intake

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Women with GDM diagnosed in 24-28 weeks.
  • Age 18-40 years.
  • Pregnancy age of 28-32 weeks.
  • Caucasian.
  • Body mass index ≤ 35Kg/m2.
  • Firs-time mother.

Exclusion Criteria:

  • Disability to understand the dietary recommendations and/or to perform self-management of glycemia, ketonuria or ketonemia.
  • A low adherence to MNT.
  • Problems with write and oral communication.
  • Other comorbidities differed of obesity, hypertension and dyslipidemia.
  • Insulin criteria within 3 first days of study (fasting glucose ≥90mg/dL, postprandial glucose 1-hour ≥140mg/dL).

Sites / Locations

  • Berta Soldevila
  • Marta Hernández

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Conventional Treatment 6 meals

Intervention Treatment 3 meals

Arm Description

Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.

Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).

Outcomes

Primary Outcome Measures

Preprandial ketonemia
Before the 3 main meals every day.
Glycemic profile below pregnancy target capillary blood glucose concentration
Self monitoring blood glucose levels: pre meals < 90 mg/dL, 1 hour post meals <140mg/dL

Secondary Outcome Measures

Area under the curve of interstitial glucose levels
Blinded continuous glucose monitoring data, iPro2, Medtronic (r)): diurnal (from 7 am to 11 pm) and nocturnal (from 11pm to 7 am)
Fetal Macrosomia
US assessed fetal weight, adjusted for national standardized charts
Newborn body weight adjusted for gestational age (national standardized charts)
Large for gestational age > 90th centile, small for gestational age < 10th centile
Newborn hypoglycemia
Serum glycemia <40 mg/dL in the first 48 hours of life
Postpartum glucose tolerance of the mother
Plasma glucose levels fasting and 120 minutes after a 75 g oral glucose load
Point-of-care glycated hemoglobin (HbA1c)
DCA Vantage Analyzer, Siemens ®

Full Information

First Posted
December 4, 2017
Last Updated
August 3, 2022
Sponsor
Germans Trias i Pujol Hospital
Collaborators
Hospital Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida, Universitat de Lleida, Fundació Institut Germans Trias i Pujol
search

1. Study Identification

Unique Protocol Identification Number
NCT03378908
Brief Title
Carbohydrates Distribution in Pregnancy Study
Acronym
CHiPS
Official Title
Medical Nutrition Therapy in Gestational Diabetes Mellitus: Comparison of Different Number of Meals. A Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
February 1, 2018 (Actual)
Primary Completion Date
September 1, 2021 (Actual)
Study Completion Date
September 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Germans Trias i Pujol Hospital
Collaborators
Hospital Arnau de Vilanova, Institut de Recerca Biomèdica de Lleida, Universitat de Lleida, Fundació Institut Germans Trias i Pujol

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Hypothesis: Patients with Gestational Diabetes Mellitus (GDM) have a high risk to develop complications during pregnancy, puerperium and in the newborn. At present there are not scientific evidences about the optimal distribution of meals in the medical nutrition therapy (MNT) and their relationship with glycemic control. Aim: To explore and compare ketonemia and glycemic profile in patients with GDM that follow a MNT distributed in 6 or 3 meals. Besides, we want to explore the differences between both treatments in glucose dynamics. Methods: The study design is a randomized, crossover and multicentric trial. A sample of 10 patients with GDM will be recruited in the Department of Endocrinology and Nutrition from both centres. In a randomized manner patients will follow the conventional treatment (a carbohydrate-controlled diet distributed in 6 meals: 3 main meals and 3 snacks) and the intervention treatment (a carbohydrate-controlled diet distributed in 3 meals: breakfast, lunch and dinner). They will be randomized to begin with one of the two treatments, and after two weeks they will be switched to the other treatment. Patients will wear a blinded continuous glucose monitoring device (iPro2-TM, Medtronic) during the entire study period. Inclusion criteria: Women with GDM diagnosed in 24-28 weeks. Age 18-40 years. Pregnancy age of 28-32 weeks. Caucasian. Body mass index ≤ 35 Kg/m2. Exclusion criteria: Unability to understand the dietary recommendations and/or to perform self-management of glycemia, ketonuria or ketonemia. A low adherence to MNT. Problems with written and/or oral communication. Presence of comorbidities other than obesity, hypertension and dyslipidemia. Insulin-need criteria within 3 first days of the beginning of the study (fasting glucose ≥90mg/dL, postprandial glucose 1-hour ≥140mg/dL). Clinical and sociodemographic variables will be assessed. Dietary records and blood samples will be collected. Daily basal ketonuria and ketonemia before each meal will be assessed. Glycemic profile will be collected with a blind-sensor during the four weeks of the intervention study. Generalized linear model analysis will be performed. Statistical power will be 80% and significance level will be set at 0.05. Written informed consent will be collected from all participants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gestational Diabetes Mellitus in Pregnancy
Keywords
medical therapy nutrition, meal, carbohydrates, intervention, food intake

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Masking Description
Glycemic profile will be collected with a blind-sensor during the study.
Allocation
Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Conventional Treatment 6 meals
Arm Type
No Intervention
Arm Description
Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
Arm Title
Intervention Treatment 3 meals
Arm Type
Experimental
Arm Description
Diet will be distributed in 3 meals (breakfast, lunch and dinner). Each meal will consist of the addition of the conventional meal and the next snack. Energy intake will be distributed: 30% breakfast (25% breakfast + 5% snack), 40% lunch (30% lunch + 10% snack) and 30% dinner (25% dinner and 5% snack).
Intervention Type
Behavioral
Intervention Name(s)
Intervention Treatment
Intervention Description
Both groups (conventional and treatment) will have the same nutritional composition, with 40% carbohydrates, 20% protein and 40% total fat (preferently monounsaturated fatty acids).
Primary Outcome Measure Information:
Title
Preprandial ketonemia
Description
Before the 3 main meals every day.
Time Frame
4 weeks (2 weeks with the conventional treatment and 2 weeks with the intervention treatment)
Title
Glycemic profile below pregnancy target capillary blood glucose concentration
Description
Self monitoring blood glucose levels: pre meals < 90 mg/dL, 1 hour post meals <140mg/dL
Time Frame
4 weeks (2 weeks with conventional treatment and 2 weeks with intervention treatment)
Secondary Outcome Measure Information:
Title
Area under the curve of interstitial glucose levels
Description
Blinded continuous glucose monitoring data, iPro2, Medtronic (r)): diurnal (from 7 am to 11 pm) and nocturnal (from 11pm to 7 am)
Time Frame
Time Frame: 4 weeks (2 weeks with conventional treatment and 2 weeks with intervention treatment)
Title
Fetal Macrosomia
Description
US assessed fetal weight, adjusted for national standardized charts
Time Frame
Through study completion, 4 weeks
Title
Newborn body weight adjusted for gestational age (national standardized charts)
Description
Large for gestational age > 90th centile, small for gestational age < 10th centile
Time Frame
At delivery
Title
Newborn hypoglycemia
Description
Serum glycemia <40 mg/dL in the first 48 hours of life
Time Frame
48 hours from delivery
Title
Postpartum glucose tolerance of the mother
Description
Plasma glucose levels fasting and 120 minutes after a 75 g oral glucose load
Time Frame
6 weeks after delivery
Title
Point-of-care glycated hemoglobin (HbA1c)
Description
DCA Vantage Analyzer, Siemens ®
Time Frame
Every 2 weeks from the date of randomization until the last visit of the study

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Women with GDM diagnosed in 24-28 weeks. Age 18-40 years. Pregnancy age of 28-32 weeks. Caucasian. Body mass index ≤ 35Kg/m2. Firs-time mother. Exclusion Criteria: Disability to understand the dietary recommendations and/or to perform self-management of glycemia, ketonuria or ketonemia. A low adherence to MNT. Problems with write and oral communication. Other comorbidities differed of obesity, hypertension and dyslipidemia. Insulin criteria within 3 first days of study (fasting glucose ≥90mg/dL, postprandial glucose 1-hour ≥140mg/dL).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Didac Mauricio, MD PHD
Organizational Affiliation
Germans Trias i Pujol Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Berta Soldevila
City
Badalona
State/Province
Barcelona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Marta Hernández
City
Lleida
ZIP/Postal Code
25196
Country
Spain

12. IPD Sharing Statement

Learn more about this trial

Carbohydrates Distribution in Pregnancy Study

We'll reach out to this number within 24 hrs